Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]
Ammar Al-Chalabi,Pamela J Shaw,Carolyn A Young,Karen E Morrison,Caroline Murphy,Marie Thornhill,Joanna Kelly,I Nicholas Steen,P Nigel Leigh,UKMND-LiCALS,Ambily Sathish,Amina Chaouch,Amy Palmer,Andrea Stutt,Andrew Dougherty,Ann Cochrane,Annette Taylor,Biruk Asfaw,C Oliver Hanemann,Carlos Guevara,Carolyn Young,Catherine Whatley,Cathy Ellis,Ceryl Harwood,Channa Hewamadduma,Chinea Eziefula,Chris Murphy,Christine Cosby,Christopher McDermott,Claire McHugh,Claire Merritt,Clare Williams,David Paling,Dave Watling,David Burn,David Rog,Dominic Sexton,Douglas Mitchell,Elizabeth Johnson,Emma Oughton,Erica Waines,Faye OKeeffe,Fiona Evans,Gemma Woods,Gill Mill,Gill Siuda,Hannah Hollinger,Hisham H M Hamdalla,Helen Beaumont-Kellner,Helen Vanek,Hugh Rickards,Ibrahim Imam,Iracema Leroi,Jan Clarke,Jane Houghton,Janice Birt,Janiki Panicker,Jennifer Smith,Joanna Glennon,Joanne Brown,John Ealing,Jonathan Anderson,Jonathan Williams,Justine Adams,Karen Morrison,Kate O'Hanlon,Katie Sidle,Kevin Talbot,Leanne Walker,Lindsey Copeland,Lokesh Wijesekera,Louise Pate,Lucy Partington-Jones,Lynne Savage,Lynne Wyatt,Marianne Hare,Martin R Turner,Mary Jo Trimmer,Meneka Sidhu,Michael Grieves,Muhammad Rafiq,Nazir Sharaf,Nichola Ritchie,Nick Davies,Nicola Maycock,Nigel Leigh,Nikolay Dimitrov,Pamela Shaw,Partha Ray,Paula Nuttall,Phil Paterson,Rachael Hibberd,Rachel Hornabrook,Rehiana Ali,Reshma Shah,Reza Sadjadi,Richard Orrell,Richard Sylvester,Robert Addison-Jones,Robin Howard,Roisin Turner,Rupert Mcshane,Saiffuddin Shaik,Samirah Anane,Sarah Dhariwal,Steven Dodds,Sue Palmer,Susie Crawford,Syed Zaidi,Tahir Majeed,Theresa McCarthy,Theresa Walsh,Tien Khoo,Tim Williams,Val Russell,Wendy Barrett
DOI: https://doi.org/10.1186/1471-2377-11-111
2011-09-21
Abstract:Background: Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative disorder characterised by loss of motor neurons leading to severe weakness and death from respiratory failure within 3-5 years. Riluzole prolongs survival in ALS. A published report has suggested a dramatic effect of lithium carbonate on survival. 44 patients were studied, with 16 randomly selected to take LiCO3 and riluzole and 28 allocated to take riluzole alone. In the group treated with lithium, no patients had died (i.e., 100% survival) at the end of the study (15 months from entry), compared to 71% surviving in the riluzole-only group. Although the trial can be criticised on several grounds, there is a substantial rationale from other laboratory studies that lithium is worth investigating therapeutically in amyotrophic lateral sclerosis. Methods/design: LiCALS is a multi-centre double-blind randomised parallel group controlled trial of the efficacy, safety, and tolerability of lithium carbonate (LiCO3) at doses to achieve stable 'therapeutic' plasma levels (0.4-0.8 mmol/L), plus standard treatment, versus matched placebo plus standard treatment, in patients with amyotrophic lateral sclerosis. The study will be based in the UK, in partnership with the MND Association and DeNDRoN (the Dementias and Neurodegnerative Diseases Clinical Research Network). 220 patients will be recruited. All patients will be on the standard treatment for ALS of riluzole 100 mg daily. The primary outcome measure will be death from any cause at 18 months defined from the date of randomisation. Secondary outcome measures will be changes in three functional rating scales, the ALS Functional Rating Scale-Revised, The EuroQOL (EQ-5D), and the Hospital Anxiety and Depression Scale.Eligible patients will have El Escorial Possible, Laboratory-supported Probable, Probable or Definite amyotrophic lateral sclerosis with disease duration between 6 months and 36 months (inclusive), vital capacity ≥ 60% of predicted within 1 month prior to randomisation and age at least18 years. Discussion: Patient recruitment began in June 2009 and the last patient is expected to complete the trial protocol in November 2011. Trial registration: Current controlled trials ISRCTN83178718.